Soluble TWEAK may predict carotid atherosclerosis in treated HIV infection

References

• Vendrell J, Chacon MR. TWEAK: a new player in obesity and diabetes. Front Immunol. 2013;4:488.
   PubMed Web of Science ®Google Scholar
• Aristoteli LP, Møller HJ, Bailey B, Moestrup SK, Kritharides L. The monocytic lineage specific soluble CD163 is a plasma marker of coronary atherosclerosis. Atherosclerosis. 2006;184(2):342–347.10.1016/j.atherosclerosis.2005.05.004
   PubMed Web of Science ®Google Scholar
• Bover LC, Cardo-Vila M, Kuniyasu A, et al. A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol (Baltimore, Md: 1950). 2007;178(12):8183–8194.
   PubMed Web of Science ®Google Scholar
• Blanco-Colio LM, Martin-Ventura JL, Munoz-Garcia B, et al. Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arteriosclerosis, Thrombosis, Vascular Biol. 2007;27(4):916–922.10.1161/01.ATV.0000258972.10109.ff
   PubMed Web of Science ®Google Scholar
• Kralisch S, Ziegelmeier M, Bachmann A, et al. Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis. 2008;199(2):440–444.10.1016/j.atherosclerosis.2007.10.022
   PubMed Web of Science ®Google Scholar
• Jelić-Ivanović Z, Bujišić N, Spasić S, et al. Circulating sTWEAK improves the prediction of coronary artery disease. Clin Biochem. 2009;42(13–14):1381–1386.10.1016/j.clinbiochem.2009.06.001
   PubMed Web of Science ®Google Scholar
• Chorianopoulos E, Rosenberg M, Zugck C, et al. Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure. European J Heart Failure. 2009;11(11):1050–1056.10.1093/eurjhf/hfp139
   PubMed Web of Science ®Google Scholar
• Martín-Ventura JL, Lindholt JS, Moreno JA, et al. Soluble TWEAK plasma levels predict expansion of human abdominal aortic aneurysms. Atherosclerosis. 2011;214(2):486–489.10.1016/j.atherosclerosis.2010.11.009
   PubMed Web of Science ®Google Scholar
• Moreno JA, Dejouvencel T, Labreuche J, et al. Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio. Arteriosclerosis, Thrombosis, Vascular Biol. 2010;30(6):1253–1262.10.1161/ATVBAHA.110.203364
   PubMed Web of Science ®Google Scholar
• Turkmen K, Tonbul HZ, Erdur FM, et al. Soluble TWEAK independently predicts atherosclerosis in renal transplant patients. BMC Nephrol. 2013;14:163.10.1186/1471-2369-14-144
   PubMed Web of Science ®Google Scholar
• Hassan SB, El-demery AB, Ahmed AI, Abukhalil RE. Soluble TWEAK and cardiovascular morbidity and mortality in chronic kidney disease patients. Arab J Nephrol Transplantation. 2012;5(1):27–32.
   PubMedGoogle Scholar
• Valdivielso JM, Coll B, Martín-Ventura JL, et al. Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease. J Nephrol. 2013;26(6):1105–1113.10.5301/jn.5000245
   PubMed Web of Science ®Google Scholar
• Fernández-Laso V, Sastre C, Valdivielso JM, et al. Soluble TWEAK levels predict the presence of carotid atherosclerotic plaques in subjects free from clinical cardiovascular diseases. Atherosclerosis. 2015;239(2):358–363.10.1016/j.atherosclerosis.2015.01.040
   PubMed Web of Science ®Google Scholar
• Burdo TH, Lo J, Abbara S, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infectious Dis. 2011;204(8):1227–1236.10.1093/infdis/jir520
   PubMed Web of Science ®Google Scholar
• Fitch kV, Srinivasa S, Abbara S, et al. Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women. J Infectious Dis. 2013;208(11):1737–1746.10.1093/infdis/jit508
   PubMed Web of Science ®Google Scholar
• Beltrán LM, Muñoz Hernández R, de Pablo Bernal RS, et al. Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection. PLoS ONE. 2014;9(3):e90541.10.1371/journal.pone.0090541
   PubMed Web of Science ®Google Scholar
• Torriani FJ, Komarow L, Parker RA, et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: the ACTG (AIDS Clinical Trials Group) study 5152s. J Am College Cardiol. 2008;52(7):569–576.10.1016/j.jacc.2008.04.049
   PubMed Web of Science ®Google Scholar
• Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infectious Dis. 2008;197(8):1133–1144.
   PubMed Web of Science ®Google Scholar
• Eckard AR, Jiang Y, Debanne SM, Funderburg NT, McComsey GA. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infectious Dis. 2014;209(8):1156–1164.10.1093/infdis/jiu012
   PubMed Web of Science ®Google Scholar
• Funderburg NT, Jiang Y, Debanne SM, et al. Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. Clin Infectious Dis: Official Publ Infectious Dis Soc Am. 2014;58(4):588–595.
   PubMed Web of Science ®Google Scholar
• Longenecker CT, Jiang Y, Orringer CE, et al. Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection. AIDS (London, England). 2014;28(7):969–977.
   PubMed Web of Science ®Google Scholar
• Longenecker CT, Funderburg NT, Jiang Y, et al Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals. HIV Med. 2013; 14(6):385–390.
   PubMed Web of Science ®Google Scholar
• Dharmapatni AA, Smith MD, Crotti TN, et al. TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis. Arthritis Res Ther. 2011;13(2):R51.10.1186/ar3294
   PubMed Web of Science ®Google Scholar
• Chicheportiche Y, Fossati-Jimack L, Moll S, Ibnou-Zekri N, Izui S. Down-regulated expression of TWEAK mRNA in acute and chronic inflammatory pathologies. Biochem Biophys Res Commun. 2000;279(1):162–165.10.1006/bbrc.2000.3913
   PubMed Web of Science ®Google Scholar
• Maecker H, Varfolomeev E, Kischkel F, et al. TWEAK attenuates the transition from innate to adaptive immunity. Cell. 2005;123(5):931–944.10.1016/j.cell.2005.09.022
   PubMed Web of Science ®Google Scholar
• Subramanian S, Tawakol A, Burdo TH, et al. Arterial inflammation in patients with HIV. JAMA. 2012;308(4):379–386.10.1001/jama.2012.6698
   PubMed Web of Science ®Google Scholar
• Matsushita N, Kashiwagi M, Wait R, et al. Elevated levels of soluble CD163 in sera and fluids from rheumatoid arthritis patients and inhibition of the shedding of CD163 by TIMP-3. Clin Exp Immunol. 2002;130(1):156–161.10.1046/j.1365-2249.2002.01963.x
   PubMed Web of Science ®Google Scholar
• Nakayama W, Jinnin M, Makino K, et al. CD163 expression is increased in the involved skin and sera of patients with systemic lupus erythematosus. Eur Journal Dermatol: EJD. 2012;22(4):512–517.
   PubMed Web of Science ®Google Scholar
• Adly AA, Ismail EA, Ibraheem TM. Macrophage-derived soluble CD163 level in young patients with Gaucher disease: relation to phenotypes, disease severity and complications. Int Immunopharmacol. 2015;24(2):416–422.10.1016/j.intimp.2014.12.039
   PubMed Web of Science ®Google Scholar
• Moreno JA, Muñoz-García B, Martín-Ventura JL, et al. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis. 2009;207(1):103–110.10.1016/j.atherosclerosis.2009.04.033
   PubMed Web of Science ®Google Scholar
• Munoz-Garcia B, Martin-Ventura JL, Martinez E, et al. Fn14 Is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin. Stroke; J Cerebral Circulation. 2006;37(8):2044–2053.10.1161/01.STR.0000230648.00027.00
   PubMed Web of Science ®Google Scholar
• Kim SH, Lee WH, Kwon BS, et al. Tumor necrosis factor receptor superfamily 12 may destabilize atherosclerotic plaques by inducing matrix metalloproteinases. Jpn Circulation J. 2001;65(2):136–138.10.1253/jcj.65.136
   PubMedGoogle Scholar
• Yilmaz MI, Sonmez A, Ortiz A, et al. Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. Clin J Am Soc Nephrol: CJASN. 2011;6(4):785–792.10.2215/CJN.09231010
   PubMed Web of Science ®Google Scholar
• Díaz-López A, Bulló M, Chacón MR, et al. Reduced circulating sTWEAK levels are associated with metabolic syndrome in elderly individuals at high cardiovascular risk. Cardiovasc Diabetol. 2014;13:51.10.1186/1475-2840-13-51
   PubMed Web of Science ®Google Scholar
• Kralisch S, Ziegelmeier M, Bachmann A, et al. Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis. 2008;199(2):440–444.10.1016/j.atherosclerosis.2007.10.022
   PubMed Web of Science ®Google Scholar
• Munoz-Garcia B, Moreno JA, Lopez-Franco O, et al. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) Enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. Arteriosclerosis, Thrombosis, Vasc Biol. 2009;29(12):2061–2068.10.1161/ATVBAHA.109.194852
   PubMed Web of Science ®Google Scholar
• Schapira K, Burkly LC, Zheng TS, et al. Fn14-Fc fusion protein regulates atherosclerosis in ApoE-/- mice and inhibits macrophage lipid uptake In vitro. Arteriosclerosis, Thrombosis, Vasc Biol. 2009;29(12):2021–2027.10.1161/ATVBAHA.109.195040
   PubMed Web of Science ®Google Scholar
• Munoz-Garcia B, Madrigal-Matute J, Moreno JA, et al. TWEAK-Fn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells. Cardiovasc Res. 2011;89(1):225–233.10.1093/cvr/cvq278
   PubMed Web of Science ®Google Scholar